Investors
  • Up to €414 million Exclusive Worldwide Licensing Agreement with Sanofi for C4XD oral IL-17A inhibitor programme

    12 April 2021 – C4X Discovery Holdings plc (AIM: C4XD), a pioneering Drug Discovery company, today announces that its subsidiary, C4X Discovery Limited (“C4XD”, “C4X Discovery” or the “Company”), has signed an exclusive worldwide licensing agreement with Sanofi (NASD: SNY, PAR: SAN - "Sanofi "), worth up to €414 million, for C4XD’s oral pre-clinical IL-17A inhibitor programme.  Under the terms of the agreement, C4XD will receive an upfront payment of €7 million and could receive up to a further €407 million in potential development, regulatory and commercialisation milestones, of which €11 million is in pre-clinical milestones, in addition to single digit royalties.

    Read more...

Investors

Welcome to the Investor Relations section of the C4X Discovery website.

This area is dedicated to keeping shareholders and potential investors up to date with share price, news and other relevant information.